Shares of Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) traded down 3.3% on Thursday . The stock traded as low as $5.32 and last traded at $5.3940. 47,724 shares traded hands during mid-day trading, a decline of 35% from the average daily volume of 72,946 shares. The stock had previously closed at $5.58.
Wall Street Analyst Weigh In
Separately, Weiss Ratings downgraded shares of Anbio Biotechnology from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, July 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.
View Our Latest Research Report on Anbio Biotechnology
Anbio Biotechnology Price Performance
Anbio Biotechnology Company Profile
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.
Read More
- Five stocks we like better than Anbio Biotechnology
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
- These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons
Receive News & Ratings for Anbio Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anbio Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
